Cargando…

Unraveling connectivity changes due to dopaminergic therapy in chronically treated Parkinson’s disease patients

The effects of dopaminergic therapy for Parkinson’s disease (PD) on the brain functional architecture are still unclear. We investigated this topic in 31 PD patients (disease duration: 11.2 ± (SD) 3.6 years) who underwent clinical and MRI assessments under chronic dopaminergic treatment (duration: 8...

Descripción completa

Detalles Bibliográficos
Autores principales: Ballarini, Tommaso, Růžička, Filip, Bezdicek, Ondrej, Růžička, Evžen, Roth, Jan, Villringer, Arno, Vymazal, Josef, Mueller, Karsten, Schroeter, Matthias L., Jech, Robert
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6156510/
https://www.ncbi.nlm.nih.gov/pubmed/30254336
http://dx.doi.org/10.1038/s41598-018-31988-0
_version_ 1783358119416430592
author Ballarini, Tommaso
Růžička, Filip
Bezdicek, Ondrej
Růžička, Evžen
Roth, Jan
Villringer, Arno
Vymazal, Josef
Mueller, Karsten
Schroeter, Matthias L.
Jech, Robert
author_facet Ballarini, Tommaso
Růžička, Filip
Bezdicek, Ondrej
Růžička, Evžen
Roth, Jan
Villringer, Arno
Vymazal, Josef
Mueller, Karsten
Schroeter, Matthias L.
Jech, Robert
author_sort Ballarini, Tommaso
collection PubMed
description The effects of dopaminergic therapy for Parkinson’s disease (PD) on the brain functional architecture are still unclear. We investigated this topic in 31 PD patients (disease duration: 11.2 ± (SD) 3.6 years) who underwent clinical and MRI assessments under chronic dopaminergic treatment (duration: 8.3 ± (SD) 4.4 years) and after its withdrawal. Thirty healthy controls were also included. Functional and morphological changes were studied, respectively, with eigenvector centrality mapping and seed-based connectivity, and voxel-based morphometry. Patients off medication, compared to controls, showed increased connectivity in cortical sensorimotor areas extending to the cerebello-thalamo-cortical pathway and parietal and frontal brain structures. Dopaminergic therapy normalized this increased connectivity. Notably, patients showed decreased interconnectedness in the medicated compared to the unmedicated condition, encompassing putamen, precuneus, supplementary motor and sensorimotor areas bilaterally. Similarly, lower connectivity was found comparing medicated patients to controls, overlapping with the within-group comparison in the putamen. Seed-based analyses revealed that dopaminergic therapy reduced connectivity in motor and default mode networks. Lower connectivity in the putamen correlated with longer disease duration, medication dose, and motor symptom improvement. Notably, atrophy and connectivity changes were topographically dissociated. After chronic treatment, dopaminergic therapy decreases connectivity of key motor and default mode network structures that are abnormally elevated in PD off condition.
format Online
Article
Text
id pubmed-6156510
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-61565102018-09-28 Unraveling connectivity changes due to dopaminergic therapy in chronically treated Parkinson’s disease patients Ballarini, Tommaso Růžička, Filip Bezdicek, Ondrej Růžička, Evžen Roth, Jan Villringer, Arno Vymazal, Josef Mueller, Karsten Schroeter, Matthias L. Jech, Robert Sci Rep Article The effects of dopaminergic therapy for Parkinson’s disease (PD) on the brain functional architecture are still unclear. We investigated this topic in 31 PD patients (disease duration: 11.2 ± (SD) 3.6 years) who underwent clinical and MRI assessments under chronic dopaminergic treatment (duration: 8.3 ± (SD) 4.4 years) and after its withdrawal. Thirty healthy controls were also included. Functional and morphological changes were studied, respectively, with eigenvector centrality mapping and seed-based connectivity, and voxel-based morphometry. Patients off medication, compared to controls, showed increased connectivity in cortical sensorimotor areas extending to the cerebello-thalamo-cortical pathway and parietal and frontal brain structures. Dopaminergic therapy normalized this increased connectivity. Notably, patients showed decreased interconnectedness in the medicated compared to the unmedicated condition, encompassing putamen, precuneus, supplementary motor and sensorimotor areas bilaterally. Similarly, lower connectivity was found comparing medicated patients to controls, overlapping with the within-group comparison in the putamen. Seed-based analyses revealed that dopaminergic therapy reduced connectivity in motor and default mode networks. Lower connectivity in the putamen correlated with longer disease duration, medication dose, and motor symptom improvement. Notably, atrophy and connectivity changes were topographically dissociated. After chronic treatment, dopaminergic therapy decreases connectivity of key motor and default mode network structures that are abnormally elevated in PD off condition. Nature Publishing Group UK 2018-09-25 /pmc/articles/PMC6156510/ /pubmed/30254336 http://dx.doi.org/10.1038/s41598-018-31988-0 Text en © The Author(s) 2018 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
spellingShingle Article
Ballarini, Tommaso
Růžička, Filip
Bezdicek, Ondrej
Růžička, Evžen
Roth, Jan
Villringer, Arno
Vymazal, Josef
Mueller, Karsten
Schroeter, Matthias L.
Jech, Robert
Unraveling connectivity changes due to dopaminergic therapy in chronically treated Parkinson’s disease patients
title Unraveling connectivity changes due to dopaminergic therapy in chronically treated Parkinson’s disease patients
title_full Unraveling connectivity changes due to dopaminergic therapy in chronically treated Parkinson’s disease patients
title_fullStr Unraveling connectivity changes due to dopaminergic therapy in chronically treated Parkinson’s disease patients
title_full_unstemmed Unraveling connectivity changes due to dopaminergic therapy in chronically treated Parkinson’s disease patients
title_short Unraveling connectivity changes due to dopaminergic therapy in chronically treated Parkinson’s disease patients
title_sort unraveling connectivity changes due to dopaminergic therapy in chronically treated parkinson’s disease patients
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6156510/
https://www.ncbi.nlm.nih.gov/pubmed/30254336
http://dx.doi.org/10.1038/s41598-018-31988-0
work_keys_str_mv AT ballarinitommaso unravelingconnectivitychangesduetodopaminergictherapyinchronicallytreatedparkinsonsdiseasepatients
AT ruzickafilip unravelingconnectivitychangesduetodopaminergictherapyinchronicallytreatedparkinsonsdiseasepatients
AT bezdicekondrej unravelingconnectivitychangesduetodopaminergictherapyinchronicallytreatedparkinsonsdiseasepatients
AT ruzickaevzen unravelingconnectivitychangesduetodopaminergictherapyinchronicallytreatedparkinsonsdiseasepatients
AT rothjan unravelingconnectivitychangesduetodopaminergictherapyinchronicallytreatedparkinsonsdiseasepatients
AT villringerarno unravelingconnectivitychangesduetodopaminergictherapyinchronicallytreatedparkinsonsdiseasepatients
AT vymazaljosef unravelingconnectivitychangesduetodopaminergictherapyinchronicallytreatedparkinsonsdiseasepatients
AT muellerkarsten unravelingconnectivitychangesduetodopaminergictherapyinchronicallytreatedparkinsonsdiseasepatients
AT schroetermatthiasl unravelingconnectivitychangesduetodopaminergictherapyinchronicallytreatedparkinsonsdiseasepatients
AT jechrobert unravelingconnectivitychangesduetodopaminergictherapyinchronicallytreatedparkinsonsdiseasepatients